<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594099</url>
  </required_header>
  <id_info>
    <org_study_id>GCR-02</org_study_id>
    <nct_id>NCT01594099</nct_id>
  </id_info>
  <brief_title>Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women</brief_title>
  <official_title>Weekly Cisplatin or Weekly Liposome Paclitaxel Concurrent Radiation Therapy in Treating Elderly People With Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Science Center of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Science Center of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficiency and safety of weekly Cisplatin&#xD;
      /Liposome paclitaxel concurrent chemoradiothrapy in the treatment of locally advanced&#xD;
      cervical cancer in elderly women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concurrent radiotherapy is the standard treatment of inoperable cervical cancer .Due to the&#xD;
      physical conditions, elderly patients usually associated with medical complications, so&#xD;
      generally just receive radiotherapy alone. Recently, some retrospective studies have shown&#xD;
      that the impact of chemotherapy did not cause an increase in the complication rate among&#xD;
      elderly patients as compared to younger patients with cervical cancer, and may improve the&#xD;
      survival when concurrent with radiotherapy. Cisplatin and paclitaxel are two effective drug&#xD;
      in treating cervical cancer, but whether they are safe enough for elderly when concurrent&#xD;
      with radiotherapy, there are no clearly reports. In this study ,we replace the conventional&#xD;
      dose chemotherapy with weekly cisplatin or lipsome paclitaxel , to compare the efficiency and&#xD;
      safety of weekly cisplatin / liposome paclitaxel concurrent chemoradiotherapy and&#xD;
      radiotherapy alone in the treatment of cervical cancer in elderly patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>1 month after the treatment completed</time_frame>
    <description>Objective Response Rate: Complete response (CR)+ Partial response (PR) rates base on RECIST evaluation system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Participants will be followed from the treatment begin to 1 month after the treatment end.</time_frame>
    <description>Record the Number of participants with adverse events and the Grades of the AE according to CTCAE v3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Control Rate</measure>
    <time_frame>Participants will be followed every year for the duration of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Free Survival Rate</measure>
    <time_frame>From date of randomization until tumor recurrence or metastasis,assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>From date of randomization until the date of death from any cause,assessed up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy plus liposome paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>irradiation</intervention_name>
    <description>EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.&#xD;
Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).</description>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.&#xD;
Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).&#xD;
Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy.</description>
    <arm_group_label>Radiotherapy plus cisplatin</arm_group_label>
    <other_name>RT+C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposome paclitaxel</intervention_name>
    <description>EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.&#xD;
Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).&#xD;
Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy.</description>
    <arm_group_label>Radiotherapy plus liposome paclitaxel</arm_group_label>
    <other_name>RT+Lp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven squamous carcinoma of cervix&#xD;
&#xD;
          2. FIGO stageⅡB and ⅢB&#xD;
&#xD;
          3. Over 65 years&#xD;
&#xD;
          4. Do not receive other treatment&#xD;
&#xD;
          5. Performance index ECOG grade 0 to 2&#xD;
&#xD;
          6. Normal ECG&#xD;
&#xD;
          7. Normal hematological parameters&#xD;
&#xD;
          8. Normal renal and liver function tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concomitant disease which may adversely affect the outcome&#xD;
&#xD;
          2. Poor nutritional status&#xD;
&#xD;
          3. Medical or psychological condition precluding treatment&#xD;
&#xD;
          4. Previous treatment&#xD;
&#xD;
          5. Concurrent treatment for any cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen M W, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Hospital of Medical College of Xi'an Jiaotong University</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>May 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>May 6, 2012</last_update_submitted>
  <last_update_submitted_qc>May 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Health Science Center of Xi'an Jiaotong University</investigator_affiliation>
    <investigator_full_name>Liu Zi</investigator_full_name>
    <investigator_title>Profesor</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>elderly women</keyword>
  <keyword>concurrent chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

